T
Theodore P. Braun
Researcher at Oregon Health & Science University
Publications - 53
Citations - 1464
Theodore P. Braun is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Myeloid leukemia & Biology. The author has an hindex of 15, co-authored 34 publications receiving 966 citations. Previous affiliations of Theodore P. Braun include University of Washington Medical Center & Claremont Colleges.
Papers
More filters
Journal ArticleDOI
Response and Resistance to BCR-ABL1-Targeted Therapies.
TL;DR: Current efforts are focused on identifying therapeutic strategies to drive deeper molecular responses, enabling more patients to attempt TKI discontinuation, and driving disease burden below the detection limit for a greater number of patients.
Journal ArticleDOI
The regulation of muscle mass by endogenous glucocorticoids.
TL;DR: The progress and potential pitfalls in the development of glucocorticoid antagonists for muscle wasting will be discussed, and fundamental mechanisms of glucOCorticoids signaling are highlighted and the mechanisms of glucose-induced muscle atrophy are detailed.
Journal ArticleDOI
Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic–pituitary–adrenal axis
Theodore P. Braun,Xinxia Zhu,Marek Szumowski,Gregory D. Scott,Aaron J. Grossberg,Peter R. Levasseur,Kathryn Graham,Sheehan Khan,Sambasivarao Damaraju,William F. Colmers,Vickie E. Baracos,Daniel L. Marks +11 more
TL;DR: Systemic and CNS-delimited inflammation triggers skeletal muscle catabolism in a manner dependent on glucocorticoid signaling.
Journal ArticleDOI
Inflammation-Induced Lethargy Is Mediated by Suppression of Orexin Neuron Activity
Aaron J. Grossberg,Xinxia Zhu,Gina M. Leinninger,Peter R. Levasseur,Theodore P. Braun,Martin G. Myers,Daniel L. Marks +6 more
TL;DR: The results demonstrate a vital role for diminished Ox signaling in mediating inflammation-induced lethargy and identifies a proximal neural target for inflammatory signaling to Ox neurons, while eliminating several others.
Journal ArticleDOI
An expanded universe of cancer targets.
William C. Hahn,Joel S. Bader,Theodore P. Braun,Andrea Califano,Paul A. Clemons,Brian J. Druker,Andrew J. Ewald,Haian Fu,Subhashini Jagu,Christopher J. Kemp,William Kim,Calvin J. Kuo,Michael T. McManus,Gordon B. Mills,Xiulei Mo,Nidhi Sahni,Stuart L. Schreiber,Jessica A. Talamas,Pablo Tamayo,Jeffrey W. Tyner,Bridget K. Wagner,William A. Weiss,Daniela S. Gerhard,Vlado Dančík,Shubhroz Gill,Bruce K. Hua,Tanaz Sharifnia,Vasanthi S. Viswanathan,Yilong Zou,Filemon S. Dela Cruz,Andrew L. Kung,Brent R. Stockwell,Jesse S. Boehm,Josh Dempster,Robert T. Manguso,Francisca Vazquez,Lee Cooper,Yuhong Du,Andrey A. Ivanov,Sagar Lonial,Carlos S. Moreno,Qiankun Niu,Taofeek K. Owonikoko,Suresh S. Ramalingam,Matthew A. Reyna,Wei Zhou,Carla Grandori,Ilya Shmulevich,Elizabeth M. Swisher,Jitong Cai,Issac S. Chan,Matthew Dunworth,Yuchen Ge,Dan Georgess,Eloise M. Grasset,Elodie Henriet,Hildur Knutsdottir,Michael G. Lerner,Veena Padmanaban,Matthew C. Perrone,Yasir Suhail,Yohannes Tsehay,Manisha Warrier,Quin Morrow,Tamilla Nechiporuk,Nicola Long,Jennifer Saultz,Andy Kaempf,Jessica Minnier,Cristina E. Tognon,Stephen E. Kurtz,Anupriya Agarwal,Jordana Brown,Kevin Watanabe-Smith,Tania Q. Vu,Thomas Jacob,Yunqi Yan,Bridget Robinson,Evan F. Lind,Yoko Kosaka,Emek Demir,Joseph Estabrook,Michael Grzadkowski,Olga Nikolova,Ken Chen,Ben Deneen,Han Liang,Michael C. Bassik,Asmita Bhattacharya,Kevin C. Brennan,Christina Curtis,Olivier Gevaert,Hanlee P. Ji,Kasper Karlsson,Kremena Karagyozova,Yuan-Hung Lo,Katherine N. Liu,Michitaka Nakano,Anuja Sathe,Amber R. Smith,Kaitlyn Spees,Wing Hing Wong,Kanako Yuki,Matt Hangauer,Dan S. Kaufman,Allan Balmain,Saumya R. Bollam,Wei-Ching Chen,Qi-Wen Fan,Kelly Kersten,Matthew F. Krummel,Yun Rose Li,Marie Menard,Nicole Nasholm,Christin Schmidt,Nina K. Serwas,Hiroyuki Yoda,Alan Ashworth,Sourav Bandyopadhyay,Trevor Bivona,Gabriel Eades,Stefan Oberlin,Neil Tay,Yuhao Wang,Jonathan S. Weissman +124 more
TL;DR: A framework is described for this expanded list of cancer targets, providing novel opportunities for clinical translation and indicating that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes.